Clinical Trial Update: A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing once-daily fluticasone furoate/vilanterol (100/25 mcg) to twice-daily fluticasone propionate/salmeterol (250/50 mcg) in chronic obstruct…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• ADVAIR DISKUS (fluticasone propionate and salmeterol)
• BREO ELLIPTA (fluticasone furoate and vilanterol trifenatate)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED | Results posted: 2014-03-05